Risk factor
Poor trading liquidity
Profitability factor
Strong growth
About
Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair
Target Price
The average target price of CPH.TO is 21.4 and suggests 31.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in